|Bid||30.74 x 800|
|Ask||31.57 x 1000|
|Day's Range||30.83 - 32.36|
|52 Week Range||8.52 - 34.51|
|Beta (5Y Monthly)||2.29|
|PE Ratio (TTM)||294.02|
|Earnings Date||Nov 30, 2021 - Dec 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.25|
Subscribe to Yahoo Finance Plus to view Fair Value for CDMOLearn more
Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seasoned Life Science Industry Executive with More Than 30 Years of Experience in Cell and Gene Therapy, Including Senior Level Viral Vector Development Positions with Fujifilm Diosynth Biotechnologies and Millipore SigmaTUSTIN, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechno
The stock market's relatively smaller companies dream of inclusion on a major equity index, as it raises their visibility and puts them on the radar of index funds. Tuesday was Avid Bioservices' (NASDAQ: CDMO) turn in the spotlight. Effective prior to the start of trading this Friday, Oct. 29, Avid will join the S&P SmallCap 600 index.